<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions other than botulinum toxin for spasticity after stroke - Lindsay, C - 2016 | Cochrane Library</title> <meta content="Pharmacological interventions other than botulinum toxin for spasticity after stroke - Lindsay, C - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010362.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions other than botulinum toxin for spasticity after stroke - Lindsay, C - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010362.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010362.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions other than botulinum toxin for spasticity after stroke" name="citation_title"/> <meta content="Cameron Lindsay" name="citation_author"/> <meta content="South Eastern Health and Social Care Trust" name="citation_author_institution"/> <meta content="Aphrodite Kouzouna" name="citation_author"/> <meta content="Keele University" name="citation_author_institution"/> <meta content="Christopher Simcox" name="citation_author"/> <meta content="Derbyshire Community Health Services" name="citation_author_institution"/> <meta content="Anand D Pandyan" name="citation_author"/> <meta content="Keele University" name="citation_author_institution"/> <meta content="a.d.pandyan@keele.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010362.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010362.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010362.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010362.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Baclofen [therapeutic use]; Botulinum Toxins, Type A [therapeutic use]; Clonidine [analogs &amp; derivatives, therapeutic use]; Diazepam [therapeutic use]; Muscle Relaxants, Central [therapeutic use]; Muscle Spasticity [*drug therapy]; Randomized Controlled Trials as Topic; Stroke [*complications]; Tolperisone [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010362.pub2&amp;doi=10.1002/14651858.CD010362.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010362\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010362\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010362.pub2",title:"Pharmacological interventions other than botulinum toxin for spasticity after stroke",firstPublishedDate:"Oct 6, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010362.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010362.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010362.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010362.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010362.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010362.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010362.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010362.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010362.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010362.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3706 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010362.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/appendices#CD010362-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/table_n/CD010362StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/table_n/CD010362StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions other than botulinum toxin for spasticity after stroke</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information#CD010362-cr-0002">Cameron Lindsay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information#CD010362-cr-0003">Aphrodite Kouzouna</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information#CD010362-cr-0004">Christopher Simcox</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information#CD010362-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Anand D Pandyan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information/en#CD010362-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010362.pub2">https://doi.org/10.1002/14651858.CD010362.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010362-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010362-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010362-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010362-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010362-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010362-abs-0001" lang="en"> <section id="CD010362-sec-0001"> <h3 class="title" id="CD010362-sec-0001">Background</h3> <p>The long‐term risk of stroke increases with age, and stroke is a common cause of disability in the community. Spasticity is considered a significantly disabling impairment that develops in people who have had a stroke. The burden of care is higher in stroke survivors who have spasticity when compared with stroke survivors without spasticity with regard to treatment costs, quality of life, and caregiver burden. </p> </section> <section id="CD010362-sec-0002"> <h3 class="title" id="CD010362-sec-0002">Objectives</h3> <p>To assess if pharmacological interventions for spasticity are more effective than no intervention, normal practice, or control at improving function following stroke. </p> </section> <section id="CD010362-sec-0003"> <h3 class="title" id="CD010362-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (May 2016), the Cochrane Central Register of Controlled Trials (CENTRAL, 2016, Issue 5), MEDLINE (1946 to May 2016), Embase (2008 to May 2016), CINAHL (1982 to May 2016), AMED (1985 to May 2016), and eight further databases and trial registers. In an effort to identify further studies, we undertook handsearches of reference lists and contacted study authors and commercial companies. </p> </section> <section id="CD010362-sec-0004"> <h3 class="title" id="CD010362-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared any systemically acting or locally acting drug versus placebo, control, or comparative drug with the aim of treating spasticity. </p> </section> <section id="CD010362-sec-0005"> <h3 class="title" id="CD010362-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed the studies for inclusion and extracted the data. We assessed the included studies for both quality and risk of bias. We contacted study authors to request further information when necessary. </p> </section> <section id="CD010362-sec-0006"> <h3 class="title" id="CD010362-sec-0006">Main results</h3> <p>We included seven RCTs with a total 403 participants. We found a high risk of bias in all but one RCT. Two of the seven RCTs assessed a systemic drug versus placebo. We pooled data on an indirect measure of spasticity (160 participants) from these two studies but found no significant effect (odds ratio (OR) 1.66, 95% confidence interval (CI) 0.21 to 13.07; I<sup>2</sup> = 85%). We identified a significant risk of adverse events per participant occurring in the treatment group versus placebo group (risk ratio (RR) 1.65, 95% CI 1.12 to 2.42; 160 participants; I<sup>2</sup> = 0%). Only one of these studies used a functional outcome measure, and we found no significant difference between groups. </p> <p>Of the other five studies, two assessed a systemic drug versus another systemic drug, one assessed a systemic drug versus local drug, and the final two assessed a local drug versus another local drug. </p> </section> <section id="CD010362-sec-0007"> <h3 class="title" id="CD010362-sec-0007">Authors' conclusions</h3> <p>The lack of high‐quality RCTs limited our ability to make specific conclusions. Evidence is insufficient to determine if systemic antispasmodics are effective at improving function following stroke. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010362-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010362-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010362-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010362-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010362-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010362-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010362-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010362-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010362-abs-0003" lang="en"> <h3>Drugs (with the exception of botulinum toxin) to treat spasticity after stroke</h3> <p><b>Question</b> </p> <p>Are drugs (with the exception of botulinum toxin) better than a placebo or control in treating spasticity in people with stroke? </p> <p><b>Background</b> </p> <p>We wanted to learn whether there was evidence for using drugs for spasticity in people with stroke, and if so, to identify whether drugs that acted on the whole body (systemic drugs) differed in their effects to drugs that acted in a localised area of the body (local drugs). </p> <p><b>Study characteristics</b> </p> <p>We included seven studies involving a total of 403 participants. The evidence is current to May 2016. There were variations among the included studies. Two of the studies were placebo controlled, while the rest compared one drug to another drug. Two studies compared two systemic drugs against each other; two studies compared two local drugs against each other; and the fifth study compared a systemic drug against a local drug. </p> <p><b>Key results</b> </p> <p>The results for the studies varied, meaning that we could make no clear conclusions. The two studies that used a placebo as a control provided conflicting results; when the results were combined we identified a slight benefit in favour of the treatment group. These two studies provided clear evidence that taking the treatment drug was likely to result in an increased risk of having an adverse event. This review identified a lack of studies and subsequent evidence relating to the use of pharmacological interventions (with the exception of botulinum toxin) to treat spasticity. Future research to identify the best time to start treatment and the optimal dose for treatment is recommended. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence varied. We judged all but one of the studies to be at high risk of bias in at least one of the six areas considered. The sample sizes in the included studies were relatively low for drug trials; three of the seven studies had 30 or fewer participants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010362-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010362-sec-0106">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010362-sec-0162">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010362-sec-0106"></div> <h3 class="title" id="CD010362-sec-0107">Implications for practice</h3> <section id="CD010362-sec-0107"> <p>There is currently insufficient high‐quality evidence to make generalisable conclusions about the effect of pharmacological interventions on spasticity in people with stroke. Furthermore, we found some very low‐quality evidence that suggests there is an increased risk of adverse effects in people who take antispasmodics when compared with placebo. We therefore cannot recommend pharmacological interventions as first‐line treatment for people with spasticity after stroke. If a clinical decision is made to administer any of these interventions, particular care should be taken to monitor for adverse effects. </p> </section> <h3 class="title" id="CD010362-sec-0108">Implications for research</h3> <section id="CD010362-sec-0108"> <p>This review has highlighted the lack of high‐quality research into the use of pharmacological interventions to treat spasticity following stroke (with the exception of botulinum toxin). </p> <p>Future research should implement high‐quality randomised trial methodology, which will help in reducing potential bias in the results. Future research should also employ placebo controls to assess the efficacy of an intervention. The use of comparative drug trials has meant we have been unable to meta‐analyse the studies, with the exception of the two studies that did use a placebo control. If a clear gold standard first‐line drug is identified, then comparative drug trials may be worthwhile in identifying novel drugs; however, this does not appear to currently be the case. If a comparison study is employed, a clear rationale for use of the comparative drug should be given. </p> <p>Future investigations should also use an assessment tool that is capable of identifying whether the drug being investigated has actually stopped the abnormal muscle activity related to spasticity from occurring. Current approaches that use indirect measures of stiffness are confounded by coexisting contractures. Only when it is evident that spasticity has been treated should methods that investigate functional changes also be measured. Even if the current review had identified a number of high‐quality placebo‐controlled trials with large sample sizes, it might not have been possible to conclude that antispasmodics were effective. If the primary impairment being measured cannot be shown to have been improved, then any functional recovery seen between groups cannot be causatively associated with the drug. </p> <p>Once these questions have been answered it will be important for future research to then focus on the optimal time at which to initiate treatments and the ideal dose associated with each treatment. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010362-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010362-sec-0022"></div> <div class="table" id="CD010362-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Systemic antispasticity drugs compared with placebo for spasticity after stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Systemic antispasticity drugs compared with placebo for spasticity after stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with spasticity following stroke<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> systemic antispasticity drugs<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Systemic antispasticity drugs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Indirect measure of spasticity</b> <br/> Modified Ashworth Scale<br/> Follow‐up: 4 or 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 1.66</b> <br/> (0.12 to 15.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>160<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 100</b> <br/> (10 to 94) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events</b> <br/> Adverse events per participant<br/> Follow‐up: 4 or 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.65</b> <br/> (1.12 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>160<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 100</b> <br/> (44 to 96) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear how random sequence generation was carried out in either study.<br/> <sup>2</sup>Results very heterogenous (I<sup>2</sup> = 90%).<br/> <sup>3</sup>The studies did not investigate the same drug against a placebo.<br/> <sup>4</sup>Both studies appeared to selectively report results. The corresponding author of the <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a> study was an employee of the company that manufactured the drug. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010362-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010362-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010362-sec-0142">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD010362-sec-0023"></div> <p>The long‐term risk of stroke increases with age. The risk of stroke over an expected lifetime has been calculated at between 1 in 5 for females and 1 in 6 for males in a group of middle‐aged adults (<a href="./references#CD010362-bbs2-0071" title="SeshadriS , BeiserA , Kelly‐HayesM , KaseCS , AuR , KannelWB , et al. The lifetime risk of stroke. Stroke2006;37(2):345‐50. ">Seshadri 2006</a>). A stroke will have a greater impact on a person than any other chronic disease (<a href="./references#CD010362-bbs2-0040" title="AdamsonJ , BeswickA , EbrahimS . Is stroke the most common cause of disability?. Journal of Stroke and Cerebrovascular Diseases2004; Vol. 13, issue 4:171‐7. ">Adamson 2004</a>). Stroke causes a range of disabilities, one of which is spasticity. The burden of care is higher in stroke patients who have spasticity when compared with stroke patients without spasticity with regard to treatment costs, quality of life, caregiver burden, and the effects of comorbidities (<a href="./references#CD010362-bbs2-0047" title="EsquenaziA . The human and economic burden of poststroke spasticity and muscle overactivity. Journal of Clinical Outcomes Management2011;18(1):34‐44. ">Esquenazi 2011</a>). </p> <section id="CD010362-sec-0024"> <h3 class="title" id="CD010362-sec-0024">Description of the condition</h3> <p>Spasticity occurs as a result of damage to the descending tracts of the upper motor neuron system. This generally involves damage to the corticoreticular pathways (para‐pyramidal pathways), tracts originating at the brain stem or reticular formation (e.g. the reticulospinal and vestibulospinal tracts) (<a href="./references#CD010362-bbs2-0043" title="BurkeD . Spasticity as an adaptation to pyramidal tract injury. Advances in Neurology1988;47:401. ">Burke 1988</a>). Such damage to the upper motor neuron system results in a loss of descending control that in turn manifests as abnormal muscle activity to an externally imposed stimuli. </p> <p>Spasticity is poorly defined in the literature (<a href="./references#CD010362-bbs2-0058" title="MalhotraS , PandyanAD , DayCR , JonesPW , HermensH . Spasticity, an impairment that is poorly defined and poorly measured. Clinical Rehabilitation2009;23(7):651‐8. ">Malhotra 2009</a>). For the purposes of this review, in order to ensure that no data were missed, we defined spasticity as "disordered sensory‐motor control, resulting from an upper motor neuron lesion, presenting as intermittent or sustained involuntary activation of muscles" (<a href="./references#CD010362-bbs2-0067" title="PandyanAD , GregoricM , BarnesMP , WoodD , vanWijckF , BurridgeJ , et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability &amp; Rehabilitation2005;27(1):2‐6. ">Pandyan 2005</a>).  </p> <p>Spasticity is common, with prevalence ranging from 30% to 80% of stroke survivors (<a href="./references#CD010362-bbs2-0057" title="MalhotraS , CousinsE , WardA , DayC , JonesP , RoffeC , et al. An investigation into the agreement between clinical, biomechanical and neurophysiological measures of spasticity. Clinical Rehabilitation2008;22(12):1105‐15. ">Malhotra 2008</a>; <a href="./references#CD010362-bbs2-0078" title="WatkinsCL , LeathleyMJ , GregsonJM , MooreAP , SmithTL , SharmaAK . Prevalence of spasticity post stroke. Clinical Rehabilitation2002;16(5):515‐22. ">Watkins 2002</a>). Spasticity that is not treated effectively can result in increased pain and stiffness, decreased range of movement, and altered posturing (<a href="./references#CD010362-bbs2-0039" title="AdaL , O'DwyerN , O'NeillE . Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disability &amp; Rehabilitation2006;28(13):891‐7. ">Ada 2006</a>; <a href="./references#CD010362-bbs2-0057" title="MalhotraS , CousinsE , WardA , DayC , JonesP , RoffeC , et al. An investigation into the agreement between clinical, biomechanical and neurophysiological measures of spasticity. Clinical Rehabilitation2008;22(12):1105‐15. ">Malhotra 2008</a>). It may also interfere with functional recovery (<a href="./references#CD010362-bbs2-0075" title="SorinolaIO , WhiteCM , RushtonDN , NewhamDJ . Electromyographic response to manual passive stretch of the hemiplegic wrist: accuracy, reliability, and correlation with clinical spasticity assessment and function. Neurorehabilitation and Neural Repair2009;23(3):287‐94. ">Sorinola 2009</a>). However, the complexity of differentiating between neural and intrinsic stiffness makes the correlation between function and spasticity difficult to identify (<a href="./references#CD010362-bbs2-0059" title="MirbagheriMM , LilaonitkulT , RymerWZ . Prediction of natural history of neuromuscular properties after stroke using Fugl‐Meyer scores at 1 month. Neurorehabilitation and Neural Repair2011;25(5):458‐68. ">Mirbagheri 2011</a>). In spite of this, many studies have used a functional measure to primarily assess the efficacy of the intervention. As the aim of rehabilitation is to facilitate and optimise the recovery of function, this review focused primarily on whether current treatments of spasticity lead to improvements in function, despite there being a lack of evidence of a causal relationship between spasticity and function. </p> </section> <section id="CD010362-sec-0025"> <h3 class="title" id="CD010362-sec-0025">Description of the intervention</h3> <p>The treatment of spasticity can be complex and relies on a multidisciplinary approach (<a href="./references#CD010362-bbs2-0041" title="BarnesMP . Management of spasticity. Age and Ageing1998;27(2):239‐45. ">Barnes 1998</a>). Treatment of spasticity has traditionally taken a stepped approach whereby conservative procedures are used first and progressively more invasive procedures are then employed (<a href="./references#CD010362-bbs2-0042" title="BogeyRA , GeisCC , BryantPR , MorozA , O'NeillBJ . Stroke and neurodegenerative disorders. 3. Stroke: rehabilitation management. Archives of Physical Medicine and Rehabilitation2004;85(3):S15‐20, S34‐40. ">Bogey 2004</a>; <a href="./references#CD010362-bbs2-0068" title="RekandT . Clinical assessment and management of spasticity: a review. Acta Neurologica Scandinavica2010;122 Suppl 190:62‐6. ">Rekand 2010</a>). Physiotherapeutic approaches are deemed the most conservative and are therefore used initially. This is reinforced by consensus guidelines (<a href="./references#CD010362-bbs2-0070" title="Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in Adults: Management Using Botulinum Toxin. National Guidelines. London: RCP, 2009. ">Royal College of Physicians 2009</a>; <a href="./references#CD010362-bbs2-0074" title="SheeanG , LanninNA , Turner‐StokesL , RawickiB , SnowBJ . Botulinum toxin assessment, intervention and after‐care for upper limb hypertonicity in adults: international consensus statement. European Journal of Neurology2010;17:74‐93. ">Sheean 2010</a>). However, physiotherapeutic interventions do not have a direct effect on abnormal muscle activity (there are some unproven claims that there may be an indirect effect) resulting from spasticity; this can only be achieved by pharmacological interventions. </p> <p>Pharmacological interventions for stroke spasticity are generally termed antispasmodics and can be divided into two groups: those that act systemically and those that act locally (<a href="./references#CD010362-bbs2-0072" title="SheeanG . Botulinum toxin treatment of adult spasticity: a benefit‐risk assessment. Drug Safety2006;29(1):31‐48. ">Sheean 2006</a>), with the locally acting treatments tending to be more invasive. The stepped approach advocates that systemically acting drugs be used initially (<a href="./references#CD010362-bbs2-0050" title="GormleyME , O'BrienCF , YablonSA . A clinical overview of treatment decisions in the management of spasticity. Muscle and Nerve Supplement1997;20(S6):S14‐20. ">Gormley 1997</a>). Such drugs include baclofen, tizanidine, or dantrolene. If these are not successful in alleviating the problem, then locally acting drugs are employed (<a href="./references#CD010362-bbs2-0042" title="BogeyRA , GeisCC , BryantPR , MorozA , O'NeillBJ . Stroke and neurodegenerative disorders. 3. Stroke: rehabilitation management. Archives of Physical Medicine and Rehabilitation2004;85(3):S15‐20, S34‐40. ">Bogey 2004</a>), such as injections of botulinum toxin to the muscles or alcohol or phenol to the peripheral nerves (<a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>). Should none of these treatments be effective, then surgery is the final treatment option. However, this is rarely used in the stroke population. </p> <p>The use of physical therapeutic methods to manage spasticity is currently being systematically reviewed (<a href="./references#CD010362-bbs2-0061" title="MonaghanK , HorganF , BlakeC , CornallC , HickeyPPM , LyonsBE , et al. Physical treatment interventions for managing spasticity after stroke. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD009188] ">Monaghan 2011</a>), as is the use of botulinum toxin, which is the most widely used locally acting pharmacological therapy (<a href="./references#CD010362-bbs2-0056" title="LyonsBE , MooreP , BhaktaBB , BamfordJM , CardwellC , LoganID . Botulinum toxin for adult spasticity after stroke or non‐progressive brain lesion [Protocol withdrawn 2013]. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002926.pub2] ">Lyons 2007</a>). However, the use of systemically acting drugs and other locally acting drugs has not been systematically reviewed. This review therefore focused on these systemically and locally acting drugs, excluding those technologies already under review (i.e. botulinum toxin and physiotherapeutic interventions).  </p> </section> <section id="CD010362-sec-0026"> <h3 class="title" id="CD010362-sec-0026">How the intervention might work</h3> <p>Drugs act either systemically or peripherally. Systemic drugs act in a number of different ways but generally aim to inhibit neurotransmitter activity at one or more sites within the central nervous system. Sites of action include both pre‐ and post‐synaptic terminals of the spinal interneurons (at varying levels of the upper motor neuron pathway), alpha motor neurons, and primary sensory afferent neurons. This inhibitory effect acts on the neurotransmitters throughout the central nervous system and can result in drowsiness amongst other side effects (<a href="./references#CD010362-bbs2-0051" title="GraciesJM , NanceP , ElovicE , McGuireJ , SimpsonDM . Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle &amp; Nerve Supplement. Wiley, 1997; Vol. 20, issue S6:S92‐120. ">Gracies 1997</a>). Administration tends to be oral, so doses need to be high for the active agent in the drug to cross the blood‐brain barrier. In order to lessen these negative effects it is possible to introduce some drugs directly into the cerebrospinal fluid via an intrathecal pump. One particular group of drugs inhibits force production at the level of the muscle; however, this effect can also be systemic. </p> <p>Other drugs are given peripherally via injection directly to the nerve. This is a far more invasive procedure; however, the systemic side effects are fewer. The aim of such injections is to destroy conduction in the nerves or the release of transmitters at the motor neuron junction or to decrease muscle contraction. </p> <p>We have provided an outline of the most regularly used drugs. While not systemically acting, we have also included alcohol and phenol in <a href="#CD010362-tbl-0002">Table 1</a>. </p> <div class="table" id="CD010362-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pharmacological agents for treating spasticity after stroke</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Generic name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Method of administration</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Method of action</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baclofen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral, intrathecal pump</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baclofen is a centrally acting gamma‐aminobutyric acid (GABA) analogue that limits the release of excitatory neurotransmitters in the spinal cord (<a href="./references#CD010362-bbs2-0063" title="MukherjeeA , ChakravartyA . Spasticity mechanisms ‐ for the clinician. Frontiers in Neurology2010;1:149. ">Mukherjee 2010</a>). It binds to GABA receptors at the presynaptic terminal and inhibits the influx of calcium into the presynaptic terminal, decreasing both mono‐ and polysynaptic reflexes (<a href="./references#CD010362-bbs2-0045" title="DavidoffRA . Antispasticity drugs: mechanisms of action. Annals of Neurology1985;17(2):107‐16. ">Davidoff 1985</a>; <a href="./references#CD010362-bbs2-0055" title="KrachLE . Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. Journal of Child Neurology2001;16(1):31‐6. ">Krach 2001</a>). It also binds on the postsynaptic terminal of the 1a sensory afferent (<a href="./references#CD010362-bbs2-0054" title="HoweJR , SutorB , ZieglgänsbergerW . Baclofen reduces post‐synaptic potentials of rat cortical neurones by an action other than its hyperpolarizing action. Journal of Physiology1987;384:539‐69. ">Howe 1987</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An imidazole derivative with agonist action on alpha‐2‐adrenergic receptors in the central nervous system (<a href="./references#CD010362-bbs2-0063" title="MukherjeeA , ChakravartyA . Spasticity mechanisms ‐ for the clinician. Frontiers in Neurology2010;1:149. ">Mukherjee 2010</a>). It has an effect both pre‐ and postsynaptically and decreases the level of excitatory neurotransmitter between the spinal interneurons to the alpha motor neurons through presynaptic inhibition (<a href="./references#CD010362-bbs2-0049" title="GallichioJE . Pharmacologic management of spasticity following stroke. Physical Therapy2004;84(10):973‐81. ">Gallichio 2004</a>). It may also inhibit abnormal activity by acting on locus coeruleus and inhibiting activity in the coerulospinal pathway (<a href="./references#CD010362-bbs2-0065" title="PalmeriA , WiesendangerM . Concomitant depression of locus coeruleus neurons and of flexor reflexes by an alpha 2‐adrenergic agonist in rats: a possible mechanism for an alpha 2‐mediated muscle relaxation. Neuroscience1990;34(1):177‐87. ">Palmeri 1990</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dantrolene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This drug acts at the muscle level rather than the neural level and affects both intra‐ and extrafusal muscles (<a href="./references#CD010362-bbs2-0049" title="GallichioJE . Pharmacologic management of spasticity following stroke. Physical Therapy2004;84(10):973‐81. ">Gallichio 2004</a>). It interferes with the release of calcium from the sarcoplasmic reticulum of the muscle (<a href="./references#CD010362-bbs2-0063" title="MukherjeeA , ChakravartyA . Spasticity mechanisms ‐ for the clinician. Frontiers in Neurology2010;1:149. ">Mukherjee 2010</a>). This decrease in available calcium reduces the force produced during a contraction (<a href="./references#CD010362-bbs2-0049" title="GallichioJE . Pharmacologic management of spasticity following stroke. Physical Therapy2004;84(10):973‐81. ">Gallichio 2004</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolperisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Centrally acting muscle relaxant that acts at the spinal cord level. Primarily acts presynaptically to inhibit both calcium and sodium channels. Decreases reflex activity by inhibiting release from the primary afferent (<a href="./references#CD010362-bbs2-0077" title="VoraA . Tolperisone. Journal of the Association of Physicians of India2010;58:127‐8. ">Vora 2010</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alcohol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of alcohol varies depending on the concentration. At concentrations below 35%, it acts as a local anaesthetic. In concentrations between 35% to 50% small‐fibre demyelination was observed, but in concentrations above this level, Wallerian degeneration and fibrosis are observed (<a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injection, intrathecal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of phenol also varies depending on concentrations used. It can be injected either into the muscle or directly into the nerve. At concentrations greater than 3%, protein denaturation and axonal degeneration destroy the neurons. 5% phenol injection to the motor points of the muscle lead to demyelination of the neuron (<a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>). </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD010362-sec-0027"> <h3 class="title" id="CD010362-sec-0027">Why it is important to do this review</h3> <p>Using antispasmodics that have systemic effects appears to remain pervasive in the clinical setting. There is evidence that global antispasmodics tend to depress the nervous system (<a href="./references#CD010362-bbs2-0051" title="GraciesJM , NanceP , ElovicE , McGuireJ , SimpsonDM . Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle &amp; Nerve Supplement. Wiley, 1997; Vol. 20, issue S6:S92‐120. ">Gracies 1997</a>; <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>). This in turn can be detrimental to motor skill acquisition (<a href="./references#CD010362-bbs2-0073" title="SheeanG . Botulinum toxin should be first‐line treatment for poststroke spasticity. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):359. ">Sheean 2009</a>; <a href="./references#CD010362-bbs2-0079" title="Willerslev‐OlsenM , Lundbye‐JensenJ , PetersenT , NielsenJ . The effect of baclofen and diazepam on motor skill acquisition in healthy subjects. Experimental Brain Research2011; Vol. 213, issue 4:465‐74. ">Willerslev‐Olsen 2011</a>). As these pharmacological therapies are started during rehabilitation, where the main objective is to relearn motor skills, such drugs may not be appropriate. There was therefore a need to review the level of evidence on which these drugs are used.  </p> <p>Phenol and alcohol are locally acting drug treatments, but their effectiveness has not been systematically reviewed with regard to poststroke spasticity, and so we have included these in our review. </p> <p>The management of spasticity poststroke using physical therapeutic means is being systematically reviewed, having been accepted as a protocol (<a href="./references#CD010362-bbs2-0061" title="MonaghanK , HorganF , BlakeC , CornallC , HickeyPPM , LyonsBE , et al. Physical treatment interventions for managing spasticity after stroke. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD009188] ">Monaghan 2011</a>), and a systematic review of botulinum toxin poststroke is currently being reviewed by editors (<a href="./references#CD010362-bbs2-0056" title="LyonsBE , MooreP , BhaktaBB , BamfordJM , CardwellC , LoganID . Botulinum toxin for adult spasticity after stroke or non‐progressive brain lesion [Protocol withdrawn 2013]. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002926.pub2] ">Lyons 2007</a>); we therefore have not included these in this review.  </p> <p>It is unclear whether one drug is more effective than another in treating both spasticity and the prevention of secondary consequences, and whether any effects translate into functional improvements. </p> <p>It is also important to assess what common adverse events are identified with the use of such drugs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010362-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010362-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010362-sec-0147">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010362-sec-0028"></div> <p>To assess if pharmacological interventions for spasticity are more effective than no intervention, normal practice, or control at improving function following stroke. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010362-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010362-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010362-sec-0148">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010362-sec-0029"></div> <section id="CD010362-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010362-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials in this review. Studies had to have investigated any pharmacological therapy; this was not limited to the drugs documented in <a href="#CD010362-tbl-0002">Table 1</a>. Systemically acting drugs tend to have a long half‐life and will therefore carry a high risk of carry‐over effect. We planned to include studies with a cross‐over design if the results of the first period of the data (i.e. before cross‐over) were available. We contacted the study authors to request this information if it was not included in the published article. Some studies combined complex combinations of pharmacological interventions with physical therapeutic interventions where there was no clear placebo or normal treatment group. We identified in the protocol that we would not include such studies, as it would be difficult to ascertain what part of the treatment provided the main effect. </p> </section> <section id="CD010362-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included participants who have had a stroke resulting in spasticity. There is evidence that spasticity is poorly defined and measured in the literature (<a href="./references#CD010362-bbs2-0058" title="MalhotraS , PandyanAD , DayCR , JonesPW , HermensH . Spasticity, an impairment that is poorly defined and poorly measured. Clinical Rehabilitation2009;23(7):651‐8. ">Malhotra 2009</a>). Excluding papers using invalid outcome measures was likely to result in very few papers left to review. We therefore included all trials that explicitly stated that the aim was to treat spasticity (it was possible to ascertain that this was the case by reading the appropriately selected papers). A variety of methods are available to measure aspects of spasticity, some that are direct (neurophysiological methods such as Hoffmann reflex (H‐reflex) and electromyography) and others that are not (biomechanical measures such as stiffness or clinical scales such as the Ashworth Scale or Tone Assessment Scale). Most of the commonly used measures are indirect and confounded (<a href="./references#CD010362-bbs2-0048" title="FleurenJF , VoermanGE , Erren‐WoltersCV , SnoekGJ , RietmanJS , HermensHJ , et al. Stop using the Ashworth scale for the assessment of spasticity. Journal of Neurology, Neurosurgery &amp; Psychiatry2010;81(1):46‐52. ">Fleuren 2010</a>). We excluded studies where no outcome measure of spasticity had been used. </p> <p>We included participants irrespective of gender and older than 18 years of age. Some studies included participants with a variety of diagnoses (e.g. traumatic brain injuries or multiple sclerosis as well as stroke). In such cases we contacted the study authors to request stroke‐specific data. If study authors were not able to provide stroke‐specific data, we still included the studies if the proportion of participants with stroke was greater than 80%. We did not include studies where the proportion of participants with stroke was less than 80%. </p> </section> <section id="CD010362-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included any pharmacological intervention that aimed to reduce spasticity regardless of dose or mode of delivery. </p> <p>We included any pharmacological intervention that was compared with a placebo, normal practice, or no intervention. We also planned to include trials that compared two forms of antispasticity intervention, as long as at least one intervention was pharmacological; however, we did not identify any such trials. </p> </section> <section id="CD010362-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>There are wide variations in the types of outcome measures used to assess the efficacy of antispasticity treatments. Many studies use a variety of scales that attempt to assess disability at the level of impairment, activity, and participation. As elucidated already, the main aim of rehabilitation is to achieve functionally relevant activity that transfers into usual activities of daily living. Such scales tend to be general and not dependent on specific areas of the body. However, other activity scales are more localised. We decided that such specific outcome measures should be divided into those assessing upper limb and those assessing the lower limb. </p> <section id="CD010362-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010362-list-0001"> <li> <p>Functional ability during activities of daily living.</p> </li> </ol> </p> </section> <section id="CD010362-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>We identified functional movement scales that measure activity at the upper limb separately to those that measure activity at the lower limb with a view to analysing them separately; however, this was not possible due to the methods used in the included studies. </p> <p> <ol id="CD010362-list-0002"> <li> <p>Secondary consequences of spasticity, assessed by specific objective measures such as pain and range of movement. </p> </li> <li> <p>Spasticity, either measured through neurophysiological methods, such as electromyographic (EMG) activity or H‐reflex activity, or using indirect measures of stiffness such as the Modified Ashworth Scale or Tone Assessment Scale. While the Modified Ashworth Scale and Tone Assessment Scale are not necessarily measures of spasticity, such measures are commonly used so we also included them.  </p> </li> <li> <p>Adverse events.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010362-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialized register' section in the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/STROKE/frame.html" target="_blank">Cochrane Stroke Group</a> module. We searched for trials in any language and attempted to arrange translation of relevant papers published in languages other than English. </p> <section id="CD010362-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Stroke Group Trials Register (last searched 19 May 2016) and the following electronic bibliographic databases and trials registers: </p> <p> <ul id="CD010362-list-0003"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 5) (<a href="./appendices#CD010362-sec-0112">Appendix 1</a>); </p> </li> <li> <p>MEDLINE (Ovid) (1946 to 17 May 2016) (<a href="./appendices#CD010362-sec-0113">Appendix 2</a>); </p> </li> <li> <p>Embase (Ovid) (2008 to 17 May 2016) (<a href="./appendices#CD010362-sec-0114">Appendix 3</a>); </p> </li> <li> <p>CINAHL (EBSCO) (1982 to 17 May 2016) (<a href="./appendices#CD010362-sec-0115">Appendix 4</a>); </p> </li> <li> <p>AMED (Ovid) (1985 to 17 May 2016) (<a href="./appendices#CD010362-sec-0116">Appendix 5</a>); </p> </li> <li> <p>Physiotherapy Evidence Database (PEDro) (<a href="http://www.pedro.org.au/" target="_blank">www.pedro.org.au/</a>) (13 May 2016); </p> </li> <li> <p>REHABDATA (<a href="http://www.naric.com/?q=en/REHABDATA" target="_blank">www.naric.com/?q=en/REHABDATA</a>) (13 May 2016); </p> </li> <li> <p>Center for International Rehabilitation Research Information and Exchange (CIRRIE) (<a href="http://cirrie.buffalo.edu/" target="_blank">cirrie.buffalo.edu/</a>) (13 May 2016); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>) (13 May 2016); </p> </li> <li> <p>EU Clinical Trials Register (<a href="http://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>) (13 May 2016); </p> </li> <li> <p>Stroke Trials Registry (<a href="http://www.strokecenter.org/trials/" target="_blank">www.strokecenter.org/trials/</a>) (13 May 2016); </p> </li> <li> <p>ISRCTN Registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>) (previously Current Controlled Trials: www.controlled‐trials.com) (13 May 2016); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (13 May 2016). </p> </li> </ul> </p> <p>We developed the MEDLINE search strategy with the help of the Cochrane Stroke Group Information Specialist and adapted it for the other databases. </p> <p>Using a comprehensive search strategy, the Cochrane Stroke Group Information Specialist has already completed a retrospective search of Embase for all stroke trials to January 2008 and added all relevant trials to the Cochrane Stroke Group Trials Register. In order to avoid duplication of efforts, we have limited the search of this database from January 2008 onwards. </p> </section> <section id="CD010362-sec-0039"> <h4 class="title">Searching other resources</h4> <p>In order to identify further published, unpublished, and ongoing trials, we:</p> <p> <ul id="CD010362-list-0004"> <li> <p>searched the reference lists of published reviews and trials identified by the above methods; </p> </li> <li> <p>contacted the following pharmaceutical companies: Novartis (baclofen) April 2014; Strathmann (tolperisone) April 2014; Sanochemia (tolperisone) April 2014; Acorda (tizanidine) April 2014; </p> </li> <li> <p>contacted authors and researchers in the field;</p> </li> <li> <p>used Science Citation Index Cited Reference Search for forward tracking of important articles. </p> </li> </ul> </p> </section> </section> <section id="CD010362-sec-0040"> <h3 class="title" id="CD010362-sec-0040">Data collection and analysis</h3> <p>Two review authors (CL and AK) independently screened the titles and abstracts of all the records obtained from the electronic searches and excluded obviously irrelevant studies. We then obtained the full text of the remaining studies, and the same two review authors independently selected studies that met the review inclusion criteria (types of studies, types of participants, aims of interventions, and outcome measures). </p> <section id="CD010362-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CL and AK) independently considered all intervention studies and identified those that were randomised controlled trials. If there was disagreement between review authors following the independent review process, we reached consensus through discussion. </p> <p>As recommended in the PRISMA statement (<a href="./references#CD010362-bbs2-0060" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Annals of Internal Medicine2009;151(4):264. ">Moher 2009</a>), we have included a flow diagram outlining the phases for selection of studies included in the review using the PRISMA template available in Review Manager 5 (<a href="./references#CD010362-bbs2-0069" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD010362-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Having identified all randomised controlled trials, two review authors (CL and CS) independently assessed each study and extracted the relevant details using a data extraction form (<a href="./appendices#CD010362-sec-0117">Appendix 6</a>) based on a modified version of the van Tulder pro‐forma previously advocated for assessment of risk of bias by the Cochrane Back Review Group (<a href="./references#CD010362-bbs2-0076" title="vanTulderMW , AssendelftWJJ , KoesBW , BouterLM , the Editorial Board of The Cochrane Collaboration Back Review Group. Method guidelines for systematic reviews in The Cochrane Collaboration Back Review Group for Spinal Disorders. Spine1997;22(20):2323‐30. ">van Tulder 1997</a>). This pro‐forma is designed to assess risk of bias, but also contains items that relate to quality and precision of reporting rather than internal validity.    </p> </section> <section id="CD010362-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CL and CS) independently assessed each study for risk of bias using Cochrane's tool for assessing risk of bias in included studies (<a href="./references#CD010362-bbs2-0053" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). In cases where there was not enough information to make a clear decision, we contacted the study authors and requested clarification or further information. We then made a decision on whether there was a low risk, high risk, or unclear risk of bias for all included studies in each of the five domains of the Cochrane 'Risk of bias' tool (<a href="./references#CD010362-bbs2-0053" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). These domains are presented as five questions. </p> <section id="CD010362-sec-0044"> <h5 class="title">Was random sequence generation adequate?</h5> <p>We deemed studies to have a low risk of bias if the study described an adequate random component in the sequence generation process. Methods might have included computer‐generated random number, coin tossing, throwing dice, or drawing lots. We considered studies to be at high risk of bias if a non‐random method for sequence generation was described. Such methods might have included birthdays, hospital numbers, or non‐random categorisation. In studies where there was not enough information to make a judgement of 'low risk' or 'high risk', we classified the study as 'unclear'. </p> </section> <section id="CD010362-sec-0045"> <h5 class="title">Was allocation adequately concealed?</h5> <p>If a centralised randomisation, computerised allocation, or the picking of opaque envelopes (which all required participant details to be provided prior to allocation) was used, then we considered concealment to be adequate. We decided to deem a study to have inadequate concealment if it included using an open list containing random numbers or contained on an open computer system. If there was no or inadequate information described in the report, then we classified the study as 'unclear'. </p> </section> <section id="CD010362-sec-0046"> <h5 class="title">Was the allocated intervention adequately concealed from the outcome assessor?</h5> <p>In studies where the outcome assessor was masked or blinded and the report did not identify any unmasking, we deemed the study to have adequate concealment. Inadequately concealed studies might have described an unblinded assessor or assessor who became unblinded. In studies where no description of the assessors masked status was described, we considered the study to be 'unclear'. </p> </section> <section id="CD010362-sec-0047"> <h5 class="title">Were incomplete outcome data adequately addressed?</h5> <p>We considered studies that reported all outcome data to have a low risk of attrition bias. In cases where there was missing data, but we deemed this data to be balanced across groups or unlikely to relate to the outcome, we considered the study to be at low risk of attrition bias. We deemed studies that inadequately addressed missing outcome data as at high risk of attrition bias. In studies where there was insufficient information to make a judgement, we deemed attrition bias to be 'unclear'. </p> </section> <section id="CD010362-sec-0048"> <h5 class="title">Were any other issues identified that increased the high risk of bias?</h5> <p>We added any additional potential sources of bias identified during the review in this section. Only those studies that were identified as having a high risk of bias were marked. If there was no clear indication of a high risk of bias, then we left the field blank. This was because a lack of reporting made it difficult to distinguish between a study that was unclear or had a low risk of bias. </p> </section> </section> <section id="CD010362-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p>By entering details from each study into Review Manager 5 (<a href="./references#CD010362-bbs2-0069" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), we were able to statistically analyse the treatment effect. The outcomes studied used a variety of data. We analysed dichotomous data as odds ratios (ORs) with 95% confidence intervals (CIs). We presented pain and the presence of side effects as dichotomous data. We also re‐coded measures of stiffness such as the Ashworth Scale into dichotomous data, identifying if there was an improvement or not. This was necessary because (as expected) there were many variations on the scale system, and it was not possible to compare such poorly defined ordinal scales as continuous data. There is also no clinically significant cutoff point available to use for these scales. </p> <p>We analysed continuous data in two ways, depending on the measures used in studies. Examples of continuous data that we analysed in this way were the H‐reflex or Barthel Index.  </p> <p>For separate studies where the same measure was used, we used the mean difference (MD) with 95% CI to calculate treatment effect. We intended to use standardised mean difference (SMD) with 95% CI in cases where separate studies used different scales to measure the same outcome; however, this was not necessary due to the lack of studies. </p> <p>As some participants could have had more than one adverse event and some participants may have had none, we analysed adverse events as risk ratio (RR) with 95% CI. </p> <p>Where an important outcome could not be summarised in the way described above, we tabulated the results. </p> </section> <section id="CD010362-sec-0050"> <h4 class="title">Unit of analysis issues</h4> <p>Due to the high risk of a carry‐over effect in cross‐over trials of systemic medications, we planned to include only studies where the the first‐period data were available (i.e. a baseline measure and then a further measure just before cross‐over).  We contacted the study authors to request these data if they were not available in the published article. </p> </section> <section id="CD010362-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>In the case of missing data we contacted the original investigators to request the information. As planned, it was possible to calculate some missing data using calculations of provided data (as might be the case in missing standard deviations). Where a study did not report a designated outcome, we excluded the study from the analyses of the outcome. </p> </section> <section id="CD010362-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We expected that the studies would be clinically heterogeneous, with variation in interventions and outcomes observed. In all instances we could observe such variation visually using the forest plot. We also used statistical methods to assess heterogeneity. We deemed a Chi<sup>2</sup> test with an χ<sup>2</sup> greater than the number of studies included minus 1 as significant heterogeneity. </p> <p>We were also able to quantify the inconsistency and impact on the meta‐analysis using the I<sup>2</sup> statistic (<a href="./references#CD010362-bbs2-0052" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>). In this meta‐analysis we set an I<sup>2</sup> statistic of up to 40% as an acceptable level of heterogeneity. </p> </section> <section id="CD010362-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>By using the search strategy outlined above to include and analyse all positive or negative available data in any language, reporting bias was kept to a minimum. We planned to subject any unpublished trials to a detailed review prior to inclusion.   </p> </section> <section id="CD010362-sec-0054"> <h4 class="title">Data synthesis</h4> <p>The aim of this review was to establish whether there is evidence of an effect. This type of review makes conducting a meta‐analysis appropriate. We expected that this review would identify studies that used a variety of drugs to achieve the same outcome, though measured in various ways. Should the pooled data from these studies demonstrate statistical homogeneity, then we intended to use a fixed‐effect meta‐analysis. We considered it more likely that we would need to use a random‐effects model. We planned to report the most conservative outcome in cases where there was divergence (<a href="./references#CD010362-bbs2-0046" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>In order to investigate the primary objective, we pooled studies using continuous data. As described in the <a href="#CD010362-sec-0049">Measures of treatment effect</a> section, for separate studies where the same measure was used, we used MD with 95% CI to calculate treatment effect; for separate studies that used different scales to measure the same outcome, we planned to employ SMD with 95% CI. </p> <p>We intended to pool the timed functional tests using SMD with 95% CI.</p> <p>In order to investigate the secondary outcomes of spasticity (and pain and secondary consequences of spasticity), we pooled studies using dichotomous outcome measures. We calculated an OR using the Mantel‐Haenszel statistical method with 95% CI to assess treatment effect. </p> <p>We intended to pool studies that used EMG or H‐reflex to assess spasticity and use MD with 95% CI to calculate treatment effect. </p> <p>In order to determine if global antispasmodic interventions are more effective than local treatments at improving function after stroke, we intended to pool studies using the same drug to study the effect of particular drugs. We intended to then pool the results of locally or globally acting drugs. </p> <p>In order to determine the rate of side effects, we planned to pool the RRs of each trial using the Mantel‐Haenszel method with 95% CI. </p> <section id="CD010362-sec-0055"> <h5 class="title">GRADE and 'Summary of findings' table</h5> <p>We used the GRADE approach to assess the quality of the evidence in the included studies. This system required two review authors (CL and AK) to assess the quality of the evidence for each individual outcome and rate it on a four‐point scale from high to very low. Randomised controlled trials began as high evidence and were sequentially downgraded from moderate to low to very low depending on the presence or lack of five factors described by <a href="./references#CD010362-bbs2-0053" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a> (see <a href="#CD010362-tbl-0003">Table 2</a>). We have presented our judgement of the quality of the evidence with reasons in <a href="./full#CD010362-tbl-0001">summary of findings Table for the main comparison</a>. </p> <div class="table" id="CD010362-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Factors that may decrease the quality of the evidence</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Limitations in the design and implementation of available studies suggesting high likelihood of bias </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Indirectness of evidence (indirect population, intervention, control, outcomes)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Imprecision of results (wide confidence intervals)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. High probability of publication bias</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD010362-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If deemed appropriate, we intended to conduct subgroup analysis to investigate if the treatment effects on the primary outcome (functional recovery) varied in subpopulations. We planned the following subgroup analyses. </p> <p> <ul id="CD010362-list-0005"> <li> <p>Time since stroke onset: to explore the effect of beginning the intervention at varying times since stroke. The subgroups were those where the intervention began within one month poststroke, within one to three months poststroke, and between three and six months poststroke. We used the mean time from stroke to intervention to identify participants that qualified for inclusion. </p> </li> <li> <p>Treatments focused specifically on arm function versus specifically on leg function.</p> </li> <li> <p>To determine if there was a difference between the side effects in drugs that were globally acting or locally acting. </p> </li> </ul> </p> </section> <section id="CD010362-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>We planned a sensitivity analysis to assess the difference between using RR and OR for the dichotomised outcomes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010362-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010362-sec-0058"></div> <section id="CD010362-sec-0059"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010362-sec-0139" title="">Characteristics of included studies</a>, <a href="./references#CD010362-sec-0140" title="">Characteristics of excluded studies</a>, <a href="./references#CD010362-sec-0141" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD010362-sec-0060"> <h4 class="title">Results of the search</h4> <p>Electronic and manual searches recovered 4064 records, of which we identified 507 as being duplicates. Following review by two review authors (CL and AK) of the remaining 3557 titles and abstracts, we selected 59 for closer review, including eight where there was no abstract available; see <a href="#CD010362-fig-0001">Figure 1</a>. After reviewing the full articles, we immediately excluded 20 articles, including all eight without an abstract, as they did not meet the initial criteria. At this point, we emailed the authors of 19 studies in which less than 80% of included participants had a diagnosis of stroke or which were cross‐over studies to request further information. As none of the authors responded, it was not possible to include these studies. We finally accepted 20 full‐text articles, of which 12 are awaiting translation and so have been placed in <a href="./references#CD010362-bbs1-0003" title="">Studies awaiting classification</a>. We therefore included eight articles. We did not identify any ongoing studies. </p> <div class="figure" id="CD010362-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010362-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010362-sec-0061"> <h4 class="title">Included studies</h4> <p>We included seven randomised controlled trials involving 403 participants (<a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a>; <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>; <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>; <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>; <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>; <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>; <a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a>); two articles reported on the same study (<a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>). </p> <section id="CD010362-sec-0062"> <h5 class="title">Design</h5> <p>Only two studies were placebo controlled (<a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>; <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>). <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a> assessed a maximum dose of 900 mg tolperisone, while <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> investigated both a maximum dose of 36 mg tizanidine and onabotulinumtoxinA against placebo. As the stated objective of this review was to exclude botulinum toxin as a drug, we have not presented the 20 participants in this trial who received onabotulinumtoxinA. We analysed these two studies together as 'systemic drug versus placebo'. </p> <p>The other five studies were all comparative studies investigating one drug against another drug. Two of these studies compared a systemic drug versus another systemic drug. Both of these studies used tizanidine as the interventional drug but used different comparator drugs: <a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> compared a maximum 12 mg tizanidine with 15 mg diazepam, and <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> compared a maximum 20 mg tizanidine against a maximum dose of 50 mg baclofen. </p> <p>One study investigated a systemic drug versus a locally acting drug (<a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a>). This study assessed a maximum dose of 24 mg tizanidine against a maximum dose of 1000 units abobotulinumtoxinA. </p> <p>The other two studies investigated a locally acting drug versus another locally acting drug (<a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>; <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>). <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> compared 3 ml of 5% phenol to 400 units onabotulinumtoxinA, while <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> compared 5 ml of 5% phenol to 5 ml of 50% ethyl alcohol. </p> <p>We have presented the results of these four distinct study groups separately.</p> </section> <section id="CD010362-sec-0063"> <h5 class="title">Sample sizes</h5> <p>The seven studies included 423 randomised participants, of which 403 participants relevant to this review were included (the remaining 20 participants were randomised to botulinum toxin in the <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> study). Two of the studies had over 100 participants each, meaning these two studies accounted for 56% of the entire sample: <a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> (105 participants) and <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a> (120 participants). The two studies that assessed a systemic drug versus a placebo had a combined total of 160 participants. The two studies that compared a systemic drug versus another systemic drug had a combined number of 135 participants (<a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a>; <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>). The one study investigating a systemic drug versus a locally acting drug had a sample size of 68 (<a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a>). The two studies that compared a locally acting drug versus another locally acting drug had notably small samples of just 10 participants in each group, therefore the combined number of participants totaled 40 (<a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>; <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>). </p> </section> <section id="CD010362-sec-0064"> <h5 class="title">Interventions</h5> <p>Despite the variety of drugs that are currently used clinically to treat spasticity, only three different drugs (tolperisone, tizanidine, and phenol) were investigated against four different control drugs (diazepam, baclofen, botulinum toxin, and alcohol). Of the three trial drugs investigated, one was a locally acting drug (phenol), and the other two were systemically acting drugs (tizanidine and tolperisone). </p> <p>Of the four control drugs used, two were locally acting (botulinum toxin or alcohol), and two were systemically acting (baclofen and diazepam). None of the studies investigated exactly the same treatments. <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> and <a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a> both compared tizanidine with botulinum toxin; however, as previously described, <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> used a placebo arm as well. This review included only data from the placebo and tizanidine arms of <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>; we will include the botulinum toxin arm when we update the review to include botulinum toxin. </p> </section> <section id="CD010362-sec-0065"> <h5 class="title">Outcomes</h5> <p>In order to assess the primary research objective, we identified outcome measures of general functional ability. Only two studies included a general functional measure (<a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>; <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>), while the other studies used measures of activity or impairment. These two studies did not fall into the same category of study design. <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> ('systemic drug versus systemic drug' design) used a functional assessment called the Pedersen scale, which is very rarely used, and dichotomised the results to improved or deteriorated. They only reported results at 12 months, despite assessments being carried out at monthly intervals up to six months and then every other month to the 12‐month assessment. We did not attempt to contact these authors, as the publication was more than 25 years old. These results are presented as odds ratio. <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a> (placebo design) assessed the Barthel Index; however, they only presented the mean difference in Barthel. As secondary anonymised data, such as standard deviation or 95% confidence interval, were not available to review, this data could not be pooled. </p> <p>We intended to investigate activity measures of the arm separately to the leg; however, given the lack of studies, this was not possible. </p> <section id="CD010362-sec-0066"> <h6 class="title">Systemic drug versus a placebo</h6> <p>The two studies that investigated a systemically acting drug versus a placebo both used functional measures, which were measured at 12 weeks. <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> used the disability assessment scale, and this data could be plotted. <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a> used two measures of functional ability; however, we were unable to analyse either. They used the two‐minute walk test, but only presented the results in graph form, and a five‐point ordinal scale of ability to perform routine activities. This was deficient in that the table only gave numbers in each group at pre‐ and end of study so that the number who improved or deteriorated was not provided. </p> </section> <section id="CD010362-sec-0067"> <h6 class="title">Systemic drug versus another systemic drug</h6> <p>The two studies that compared a systemic drug against another systemic drug both measured a functional outcome. <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> used the Pedersen scale but also used a patient self assessment of disability. The only stated result for the latter measure was an improvement from baseline to 12 months (P &lt; 0.001) in both groups, but there was no significant difference between groups. <a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> measured walking distance over flat ground and rough ground at eight weeks from baseline. The study authors did not provide information of how the distance was achieved, as they did not detail whether it was a timed walk or an endurance‐limited distance where the participant stopped when they could do no more. As fewer participants were able to complete the walk on rough ground, only the results of the flat ground were used. The mean distance and standard deviation at baseline and eight weeks were provided. In order to assess efficacy, we subtracted the mean outcome measures at eight weeks from baseline. We calculated the corresponding standard deviation (with an assumption for equal variance) using methodology described in <a href="./references#CD010362-bbs2-0044" title="DanielWW . Biostatistics: A Foundation for Analysis in the Health Sciences. 7th Edition. London: Wiley and Sons, 1999. ">Daniel 1999</a>. </p> </section> <section id="CD010362-sec-0068"> <h6 class="title">Systemic drug versus a locally acting drug</h6> <p>In the one study that investigated a systemic drug against a locally acting drug, the baseline Action Research Arm Test (ARAT) scores showed a significant difference between groups (P &lt; 0.001) (<a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a>). We used the same methodology as that of <a href="./references#CD010362-bbs2-0044" title="DanielWW . Biostatistics: A Foundation for Analysis in the Health Sciences. 7th Edition. London: Wiley and Sons, 1999. ">Daniel 1999</a> to estimate the corresponding standard deviation, having subtracted the mean outcome measures at 12 weeks from baseline. </p> </section> <section id="CD010362-sec-0069"> <h6 class="title">Locally acting drug versus another locally acting drug</h6> <p>Of the two studies that compared a locally acting drug against another locally acting drug, <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> reported that visual analysis of gait showed that all participants in both groups improved from baseline; however, the time at which this gait assessment was completed was not described. This was the only outcome in this study that related to function. <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> used a 25‐foot timed walk to measure function, which was completed at eight and 12 weeks postintervention. The report provided the mean difference between baseline and 12 weeks with standard deviation. </p> <p>As expected, the scales used to assess spasticity were diverse. Three studies used the Ashworth scale (<a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>; <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>; <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>), three used a Modified Ashworth Scale (<a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>; <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>; <a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a>), and <a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> used a novel ordinal scale with similarities to the Ashworth Scale. As described in the <a href="#CD010362-sec-0029">Methods</a>, we planned to dichotomise the data, and we performed this for five of the studies. We contacted the authors of the two studies in which only the mean and standard deviation data were provided, but they did not respond (<a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>; <a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a>). </p> <p>Only <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> used an outcome measure that directly assessed the abnormal muscle activity that is specific to spasticity. This study presented a number of neurophysiological measures (see <a href="./references#CD010362-sec-0139" title="">Characteristics of included studies</a>); however, only the H‐reflex and H(max):M(max) ratio were analysed. </p> <p>Other measures of abnormal muscle activity included muscle spasms and clonus as reported by <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> and <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>. These two studies also provided results of change in range of movement at a joint; however, <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> only provided a mean change with no other data. </p> <p>Adverse events were universally reported. They fell into three defined categories (adverse events per participant, total adverse events reported, and number of participants withdrawn due to side effects), with some studies reporting just one of these categories, and others reporting two of the categories. We were able to pool all the data from each category in the form of risk ratios. </p> </section> </section> </section> <section id="CD010362-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded 19 studies (see <a href="./references#CD010362-bbs1-0002" title="">Excluded studies</a>). We excluded them on the grounds that less than 80% of the participants had a diagnosis of stroke (11 studies: <a href="./references#CD010362-bbs2-0010" title="BurkeD , HammondC , SkuseN , JonesRF . A phenothiazine derivative in the treatment of spasticity. Journal of Neurology, Neurosurgery &amp; Psychiatry1975; Vol. 38, issue 5:469‐74. ">Burke 1975</a>; <a href="./references#CD010362-bbs2-0012" title="CarusoG , FelsA , SantoroL , PerrettiA . Effects of dantrolene sodium on pyramidal hypertonia. Clinico‐electrophysiological study. Acta Neurologica1977; Vol. 32, issue 6:872‐83. ">Caruso 1977</a>; <a href="./references#CD010362-bbs2-0013" title="ChipmanM , KaulS , LambieM . Efficacy of dantrolene sodium in the treatment of spasticity. Diseases of the Nervous System1974;35(9):427‐31. ">Chipman 1974</a>; <a href="./references#CD010362-bbs2-0015" title="GlassA , HannahA . A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia1974; Vol. 12, issue 3:170‐4. ">Glass 1974</a>; <a href="./references#CD010362-bbs2-0016" title="HarveyMS . A comparative trial of dimethothiazine in spastic conditions. A report from the General Practitioner Research Group. Practitioner1974;213:101‐5. ">Harvey 1974</a>; <a href="./references#CD010362-bbs2-0018" title="KnutssonE , MartenssonA , GransbergL . Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. Journal of the Neurological Sciences1982;53(2):187‐204. ">Knutsson 1982</a>; <a href="./references#CD010362-bbs2-0019" title="MancaM , MerloA , FerraresiG , CavazzaS , MarchiP . Botulinum toxin type A versus phenol. A clinical and neurophysiological study in the treatment of ankle clonus. European Journal of Physical and Rehabilitation Medicine2010;46(1):11‐8. ">Manca 2010</a>; <a href="./references#CD010362-bbs2-0023" title="MeythalerJM , Guin‐RenfroeS , JohnsonA , BrunnerRM . Prospective assessment of tizanidine for spasticity due to acquired brain injury. Archives of Physical Medicine and Rehabilitation2001; Vol. 82, issue 9:1155‐63. ">Meythaler 2001a</a>; <a href="./references#CD010362-bbs2-0024" title="MonsterAW , HermanR , MeeksS , McHenryJ . Cooperative study for assessing the effects of a pharmacological agent on spasticity. American Journal of Physical Medicine1973; Vol. 52, issue 4:163‐88. ">Monster 1973</a>; <a href="./references#CD010362-bbs2-0025" title="MonsterAW . Spasticity and the effect of dantrolene sodium. Archives of Physical Medicine and Rehabilitation1974; Vol. 55, issue 8:373‐83. ">Monster 1974</a>; <a href="./references#CD010362-bbs2-0026" title="ThompsonJ . Carisoprodol in the treatment of muscle spasticity in the elderly. Gerontologia Clinica1966;8(2):100‐5. ">Thompson 1966</a>), or that a cross‐over trial method had been used and the pre cross‐over data were not available (8 studies; <a href="./references#CD010362-bbs2-0008" title="BasmajianJV , ShankardassK , RussellD . Ketazolam treatment for spasticity: double‐blind study of a new drug. Archives of Physical Medicine and Rehabilitation1984;65(11):698‐701. ">Basmajian 1984</a>; <a href="./references#CD010362-bbs2-0009" title="BovierP , CambierJ , MorselliPL . Double‐blind trial of progabide in the treatment of spastic syndrome. Therapie1985;40(3):181‐5. ">Bovier 1985</a>; <a href="./references#CD010362-bbs2-0011" title="BurtAA , CurrieS . A double blind controlled trial of baclofen and diazepam in spasticity due to cerebrovascular lesions. Baclofen: Spasticity and Cerebral Pathology. 1st Edition. Cambridge: Cambridge Medical, 1978:77‐9. ">Burt 1978</a>; <a href="./references#CD010362-bbs2-0014" title="CivardiC , NaldiP , CantelloR , GianelliM , MutaniR . Protirelin tartrate (TRH‐T) in upper motoneuron syndrome: a controlled neurophysiological and clinical study. Italian Journal of Neurological Sciences1994;15(8):395‐406. ">Civardi 1994</a>; <a href="./references#CD010362-bbs2-0017" title="KatrakPH , ColeAM , PoulosCJ , McCauleyJC . Objective assessment of spasticity, strength, and function with early exhibition of Dantrolene sodium after cerebrovascular accident: a randomized double‐blind study. Archives of Physical Medicine and Rehabilitation1992; Vol. 73, issue 1:4‐9. ">Katrak 1992</a>; <a href="./references#CD010362-bbs2-0020" title="MaupasE , MarqueP , RoquesCF , Simonetta‐MoreauM . Modulation of the transmission in group II heteronymous pathways by tizanidine in spastic hemiplegic patients. Journal of Neurology, Neurosurgery &amp; Psychiatry2004;75(1):130‐5. ">Maupas 2004</a>; <a href="./references#CD010362-bbs2-0021" title="MedaerR , HellebuykH , Van DenBrandeE , SaxenaV , ThijsM , KovacsL , et al. Treatment of spasticity due to stroke. A double‐blind, cross‐over trial comparing baclofen with placebo. Acta Therapeutica1991;17(4):323‐31. ">Medaer 1991</a>; <a href="./references#CD010362-bbs2-0022" title="MeythalerJM , Guin‐RenfroeS , BrunnerRC , HadleyMN . Intrathecal baclofen for spastic hypertonia from stroke. Stroke. Department of Physical Medicine and Rehabilitation, Division of Neurological Surgery, University of Alabama at Birmingham School of Medicine, Birmingham, USA. JMeythal@uab.edu, 2001; Vol. 32, issue 9:2099‐109. ">Meythaler 2001</a>). We specified these two criteria in the protocol and attempted to contact the lead author, corresponding author, or both to obtain the data needed to include the study. </p> <p>The eight cross‐over studies had a mean (and median) date of publication of 1991 (range 1978 to 2004). This is compared to the included studies, where date of publication was mean 2002 and median 2005 (range 1988 to 2013). </p> <section id="CD010362-sec-0071"> <h5 class="title">Interventions of excluded studies</h5> <p>A total of 10 drugs were investigated in the 19 excluded trials, reflecting the diversity of potential drugs available. Five of these 19 studies investigated dantrolene. None of the included studies investigated this drug, despite its widespread clinical use. </p> </section> <section id="CD010362-sec-0072"> <h5 class="title">Studies awaiting classification</h5> <p>Twelve studies are awaiting classification (see <a href="./references#CD010362-sec-0141" title="">Characteristics of studies awaiting classification</a>). All of these studies require translation into English: four studies are Russian (<a href="./references#CD010362-bbs2-0030" title="GekhtAB , BurdGS , SelikhovaMV , IaishF , BeliakovVV . Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova1998;98(10):22‐9. ">Gekht 1998</a>; <a href="./references#CD010362-bbs2-0032" title="KovalchukVV , SkorometsAA , Vasil'evaIV . Comparative efficacy of different muscle relaxants in the rehabilitation of post‐stroke patients with spasticity. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova2008;108(8):14‐9. ">Kovalchuk 2008</a>; <a href="./references#CD010362-bbs2-0033" title="KovalchukVV . Evaluation of efficacy and safety of Mydocalm in the early rehabilitation of stroke. Zhurnal Nevrologii I Psihiatrii Imeni SS Korsakova2013; Vol. 113, issue 4:35‐40. ">Kovalchuk 2013</a>; <a href="./references#CD010362-bbs2-0036" title="StamenovaP , KoytchevR , KuhnK , HanasenC , HorvathF , RammS , et al. A randomized, double blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova2006; Vol. 106, issue 1:34‐42. ">Stamenova 2006</a>), three are in Chinese (<a href="./references#CD010362-bbs2-0028" title="CuiL‐H , ZhangT , YangL‐Y . Efficacy of three antispasmodics on limb spasticity in patients after stroke: a comparative analysis. Chinese Journal of Cerebrovascular Diseases2009;6(9):466‐70. ">Cui 2009</a>; <a href="./references#CD010362-bbs2-0029" title="GanZ , XiaoW‐M , ChenY‐K . Eperisone in the treatment of hypermyotonia following stroke: a randomised controlled observation. Chinese Journal of Clinical Rehabilitation2004;8(13):2412‐3. ">Gan 2004</a>; <a href="./references#CD010362-bbs2-0038" title="YaoJ‐R , WangD‐S , NiX‐B , RongD‐M , ZhengH‐M . Efficacy of baclofen combined with rehabilitation training in stroke patients with spastic hemiplegia. Chinese Journal of Clinical Rehabilitation2004;8(10):1814‐5. ">Yao 2004</a>), and the rest are in Dutch (<a href="./references#CD010362-bbs2-0037" title="WeynantsL , VanLaereM . Tizanidine in the treatment of spasticity in patients with hemiplegia caused by CVA or brain trauma. Acta Belgica Medica Physica1990;13(1):19‐22. ">Weynants 1990</a>), Polish (<a href="./references#CD010362-bbs2-0034" title="MusiolA , KazibutowskaZ , KurzbauerH . Lioresal in the treatment of hemiplegia. Clinical and electromyographic evaluation. Preliminary report. Neurologia i Neurochirurgia Polska1977;11(6):661‐7. ">Musiol 1977</a>), Italian (<a href="./references#CD010362-bbs2-0035" title="PratiR , SorianiS . Use of beta‐(p‐clorophenil)‐gamma‐aminobutirric acid in the treatment of hemiplegic patients with hypertonius. Rivista di Patologia Nervosa e Mentale1974;95(5):651‐2. ">Prati 1974</a>), Spanish (<a href="./references#CD010362-bbs2-0027" title="ArbizuTx , MartinezJA , RubioF , AguilarM , PerezJ . Clinical evaluation and tolerance of tizanidine (DS 103‐282) and baclofen in patients with chronic spasticity due to cerebrovascular accidents. Revista Espanola de Neurologia1988;3:291‐6. ">Arbizu 1988</a>), and Korean (<a href="./references#CD010362-bbs2-0031" title="KimDY , ParkC , NaS , ParkYS . Quantitative assessment of the effect of tizanidine on spasticity in stroke patients. Journal of the Korean Academy of Rehabilitation Medicine2003;27:471‐9. ">Kim 2003</a>). </p> <p>These studies appear to have much larger sample sizes; for 10 studies where we could identify the numbers recruited, there were a total of 964 participants. </p> </section> </section> </section> <section id="CD010362-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of our judgement for each potential form of bias across the included studies is provided in the 'Risk of bias' graph in <a href="#CD010362-fig-0002">Figure 2</a>. Our assessment of risk of bias for each individual study can be found in the <a href="./references#CD010362-sec-0139" title="">Characteristics of included studies</a> table. The risk of bias for each individual study is presented in a figurative form in the 'Risk of bias' summary in <a href="#CD010362-fig-0003">Figure 3</a>. This helps identify that only one study did not have a high risk of bias in any area. </p> <div class="figure" id="CD010362-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010362-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010362-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010362-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>A poor response from study authors for further information necessitated our assigning an unclear risk of bias as a large proportion of our judgements. With the exception of <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>, no other study authors responded to our requests for further information. </p> <section id="CD010362-sec-0074"> <h4 class="title">Allocation</h4> <p>Random sequence generation and allocation concealment were poorly described in all studies. As study authors did not respond to our requests for further information, we had to assess all of these studies as unclear risk of bias. Only <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> described the sequence generation, which was by pitch and toss. </p> </section> <section id="CD010362-sec-0075"> <h4 class="title">Blinding</h4> <p>Performance bias (blinding of participants and physician) tended to be well reported, and we were able to make a clear decision from the study reports in many cases; however, this was not the case with detection bias (blinding of outcome assessors), which was poorly reported. Due to this we classified four of the seven studies as at unclear risk of bias (<a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a>; <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>; <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>; <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>). </p> </section> <section id="CD010362-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>There was a good level of reporting on participants lost to follow‐up in many studies, and in some cases no one was lost to follow‐up, allowing us to make a clear decision on whether there was attrition bias. </p> </section> <section id="CD010362-sec-0077"> <h4 class="title">Selective reporting</h4> <p>We found the highest risk of bias to be in the selective reporting of data. Four of the seven studies did not adequately report all the outcome measures described in the methodology. We reviewed ClinicalTrials.gov and other potential resources to identify whether results had been registered in open access public forums, but this was not the case. </p> </section> <section id="CD010362-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>We identified where commercial involvement appeared to have occurred in <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>, with the corresponding author an employee of the drug company. Based on the available information, it was not possible to identify any other sources of bias in the studies. </p> </section> </section> <section id="CD010362-sec-0079"> <h3 class="title" id="CD010362-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD010362-tbl-0001"><b>Summary of findings for the main comparison</b> Systemic antispasticity drugs compared with placebo for spasticity after stroke</a> </p> <p>See <a href="./full#CD010362-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>As described, there were four distinct groups of studies, and we made comparisons between studies that for each of these four categories. </p> <section id="CD010362-sec-0080"> <h4 class="title">Systemically acting drug versus a placebo</h4> <section id="CD010362-sec-0081"> <h5 class="title">Functional ability during activities of daily living</h5> <p>Of the two studies that assessed a systemic drug against a placebo (<a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>; <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>), only <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> employed any usable measure of function (Disability Assessment Scale). The mean difference (MD) between the group receiving tizanidine (n = 21) and the group receiving placebo (n = 19) was not significant (MD ‐0.2, 95% confidence interval (CI) ‐0.9 to 0.5; <a href="./references#CD010362-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD010362-sec-0082"> <h5 class="title">Spasticity: indirect measure</h5> <p>Both of these studies had the measures of spasticity dichotomised; however, this produced very heterogenous results (I<sup>2</sup> = 85%). While the results of <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> were non‐significant, <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a> showed a significant benefit for the treatment group. When we pooled the data (160 participants), we did not identify any significant effect (odds ratio (OR) 1.66, 95% CI 0.21 to 13.07; <a href="./references#CD010362-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD010362-sec-0083"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a> reported two of the three defined categories of adverse events (adverse events per participant and withdrawals due to side effects), while <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> reported all three categories, including the total number of adverse events reported. The combined data from both studies (160 participants) on adverse events with a possible causal relationship to drug per participant demonstrated a statistically significant (P = 0.01) risk to participants receiving the treatment drug compared with placebo (risk ratio (RR) 1.65, 95% CI 1.12 to 2.42). There was very little heterogeneity in these results (I<sup>2</sup> = 0%) (<a href="./references#CD010362-fig-0006" title="">Analysis 1.3</a>). <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a> also found the total number of adverse events reported in each group to be different. Ten adverse events were reported in the 19 participants receiving placebo, whereas 24 adverse events were reported in 21 participants receiving treatment. </p> <p>Despite the homogeneity of results for adverse events per participant, the two studies reported very heterogenous results on numbers withdrawn due to side effects (I<sup>2</sup> = 62%). We therefore did not identify any significant results (RR 1.16, 95% CI 0.04 to 34.40; 160 participants). </p> </section> </section> <section id="CD010362-sec-0084"> <h4 class="title">Systemic drug versus another systemic drug</h4> <section id="CD010362-sec-0085"> <h5 class="title">Functional ability during activities of daily living</h5> <p>The two studies that compared one systemic drug against another systemic drug measured functional change in different ways (<a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a>; <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>). </p> <p><a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> compared tizanidine against diazepam and assessed benefit using a distance‐walked test over flat ground (metres) as a functional measure (79 participants, as not all participants could walk). The study report stated that "only the patients on tizanidine showed a statistically significant improvement in walking distance on flat ground"; however, both groups achieved a statistically significant improvement in distance walked. Indeed, there was a statistically significant difference (P = 0.01) between groups in favour of diazepam when we calculated mean change from baseline to eight weeks (MD ‐183.30, 95% CI ‐330.40 to ‐36.20; <a href="./references#CD010362-fig-0007" title="">Analysis 2.1</a>). </p> <p><a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> compared tizanidine against baclofen and assessed benefit using dichotomised data from the Pedersen scale, to measure function, and presented the arm and leg scores separately (30 participants). Both groups made equal improvements in the arm and leg function, so there was no difference between groups for the arm measure (OR 1.0, 95% CI 0.23 to 4.31) and the leg measure (OR 1.0, 95% CI 0.17 to 5.98; <a href="./references#CD010362-fig-0008" title="">Analysis 2.2</a>). </p> </section> <section id="CD010362-sec-0086"> <h5 class="title">Spasticity: indirect measure</h5> <p>Although the two studies used different scales to measure spasticity, the response to treatment was dichotomised to identify responders. However, we did not pool the results, as the compared drugs in each study were different. No significant differences between drugs were identified in either study: <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> compared tizanidine with baclofen (30 participants) and identified no significant difference between groups (OR 2.36, 95% CI 0.36 to 15.45), and <a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> compared tizanidine and diazepam (78 participants) and identified no significant difference between groups (OR 0.90, 95% CI 0.37 to 2.20; <a href="./references#CD010362-fig-0009" title="">Analysis 2.3</a>). </p> </section> <section id="CD010362-sec-0087"> <h5 class="title">Clonus and muscle spasms</h5> <p>Both studies also dichotomised signs of abnormal muscle activity (e.g. clonus or muscle spasms) using customised scales. Not all participants in the group had these signs, so the sample sizes in the analyses were smaller than the study sample sizes. Both studies presented the improvement in clonus. In <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> five out of seven participants improved on tizanidine, compared with four out of five on baclofen (0.63, 95% CI 0.04 to 9.65; 12 participants), whereas in <a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> 14 out of 29 participants in the tizanidine group improved, compared with eight out of 20 on diazepam (1.40, 95% CI 0.44 to 4.44; 49 participants). Both studies showed no significant differences between groups (<a href="./references#CD010362-fig-0010" title="">Analysis 2.4</a>). In addition to clonus, <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> also assessed muscle spasms, which were improved in five out of eight participants receiving tizanidine and five out of six participants receiving baclofen (0.33, 95% CI 0.03 to 4.40; 14 participants; <a href="./references#CD010362-fig-0011" title="">Analysis 2.5</a>). </p> </section> <section id="CD010362-sec-0088"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> reported two of the three defined categories adverse events (total adverse events and withdrawals due to side effects), while <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> reported all three categories, including the number of adverse events per participant. In <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> there was no significant difference between groups in the number of adverse events per participant (RR 2.10, 95% CI 0.83 to 5.30; 29 participants). In both studies there were a greater number of total adverse events in the tizanidine groups when compared with either of the comparative drugs. While this difference was not significant in <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> (RR 1.26, 95% CI 0.94 to 1.69; 29 participants), there was a significant difference (P = 0.04) in favour of diazepam in <a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> (RR 1.22, 95% CI 1.01 to 1.48; 105 participants). </p> <p>In both studies more participants were withdrawn from the control group when compared with the tizanidine group; however, this was not significant. <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a> identified a non‐significant RR of 0.13 (95% CI 0.01 to 2.38), while <a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a> found an RR of 0.42 (95% CI 0.18 to 1.01) (<a href="./references#CD010362-fig-0012" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD010362-sec-0089"> <h4 class="title">Systemic drug versus a locally acting drug</h4> <section id="CD010362-sec-0090"> <h5 class="title">Functional ability during activities of daily living</h5> <p><a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a> (68 participants) compared tizanidine against abobotulinumtoxinA and used the Action Research Arm Test (ARAT) as the outcome measure. We calculated the mean difference from baseline to week 12 and identified a significant difference (P = 0.02) in favour of botulinum toxin (MD 3.8, 95% CI ‐6.93 to ‐0.65; <a href="./references#CD010362-fig-0013" title="">Analysis 3.1</a>). </p> </section> <section id="CD010362-sec-0091"> <h5 class="title">Spasticity</h5> <p>This study did not present the results in a way that allowed any measure of spasticity to be dichotomised. We contacted the corresponding author using the email address provided but did not receive a response. </p> </section> <section id="CD010362-sec-0092"> <h5 class="title">Adverse events</h5> <p>Adverse events were only presented as number of participants withdrawn due to side effects. This showed a significant risk ratio in favour of botulinum toxin (RR 41.00, 95% CI 2.6 to 651.7; P = 0.009; 68 participants; <a href="./references#CD010362-fig-0014" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD010362-sec-0093"> <h4 class="title">Locally acting drug against another locally acting drug</h4> <section id="CD010362-sec-0094"> <h5 class="title">Functional ability during activities of daily living</h5> <p><a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> and <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> both compared phenol injections against another locally acting drug (alcohol and onabotulinumtoxinA, respectively). <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> only measured change at the level of impairment, whereas <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> (20 participants) identified no significant mean difference between groups at 12 weeks in a 25‐foot timed walk test (MD 2.70, 95% CI ‐2.83 to 8.23; <a href="./references#CD010362-fig-0015" title="">Analysis 4.1</a>). </p> </section> <section id="CD010362-sec-0095"> <h5 class="title">Passive range of movement</h5> <p>Both studies provided information on range of movement at the ankle; however, <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> only presented the mean change and no other information with which to analyse the data. <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> presented this data, which once again showed no significant difference between the two comparison drugs (P = 0.84; <a href="./references#CD010362-fig-0016" title="">Analysis 4.2</a>). </p> </section> <section id="CD010362-sec-0096"> <h5 class="title">Spasticity: neurophysiological</h5> <p>Neither of the neurophysiological outcome measures used in <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> (20 participants) demonstrated a significant difference between the groups. The mean difference between the H(max):M(max) ratio was ‐0.01 (95% CI ‐0.48 to 0.46; P = 0.97), and the mean difference in H‐reflex (amplitude) was 1.24 (95% CI ‐1.44 to 3.92; P = 0.36; <a href="./references#CD010362-fig-0017" title="">Analysis 4.3</a>). </p> </section> <section id="CD010362-sec-0097"> <h5 class="title">Spasticity: indirect measure</h5> <p><a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> (20 participants) provided dichotomised data for the modified Ashworth scale only at the six‐month assessment but reported that all 20 participants had a decrease in the scale immediately after the injection. This benefit was still present at six‐month follow‐up in nine of the 10 participants treated with alcohol and seven of the 10 in the phenol group, indicating no significant difference between groups (OR 0.26, 95% CI 0.02 to 3.06; <a href="./references#CD010362-fig-0018" title="">Analysis 4.4</a>). </p> </section> <section id="CD010362-sec-0098"> <h5 class="title">Clonus</h5> <p>In <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> the dichotomised results of clonus improvement showed that all five participants treated with phenol and four of seven participants treated with alcohol improved in clonus score. There was no significant difference between the groups (OR 8.56, 95% CI 0.34 to 212.94; <a href="./references#CD010362-fig-0019" title="">Analysis 4.5</a>). </p> </section> <section id="CD010362-sec-0099"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> and <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a> both reported the total adverse events occurring in the study. In both studies three of the 10 participants in the phenol groups reported adverse events while none of the 10 participants in the control groups reported any adverse events. There was no significant difference between groups (RR 7.0, 95% CI 0.41 to 120.16; P = 0.18 ; I<sup>2</sup> = 0%). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010362-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010362-sec-0100">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010362-sec-0156">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010362-sec-0100"></div> <section id="CD010362-sec-0101"> <h3 class="title" id="CD010362-sec-0101">Summary of main results</h3> <p>We identified seven randomised controlled trials with a combined sample size of 403 participants that investigated a pharmacological intervention for spasticity after stroke. </p> <p>Just two of these studies were placebo‐controlled trials, whereas in the other five trials one drug was compared against another drug. Only three different drugs (tolperisone, tizanidine, and phenol) were investigated against four different control drugs (diazepam, baclofen, botulinum toxin, and alcohol), and none of the studies compared the same two drugs. We were able to pool data from the two placebo trials with a combined sample size of 160 participants (<a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>; <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>). </p> <p>In addition to the two placebo studies, the studies could be divided into three further categories. Two compared two systemic drugs (<a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a>; <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>); one compared a systemic drug with a local drug (<a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a>); and two compared two local drugs (<a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>; <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>). </p> <p>Six studies used at least one functional outcome measure; however, the results were not always reported in such a way as to allow for data extraction and analyses (<a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a>; <a href="./references#CD010362-bbs2-0002" title="KirazliY , OnAY , KismaliB , AksitR . Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double‐blind trial. American Journal of Physical Medicine &amp; Rehabilitation1998; Vol. 77, issue 6:510‐5. OnAY , KirazliY , KismaliB , AksitR . Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow‐up. American Journal of Physical Medicine &amp; Rehabilitation1999;78(4):344‐9. ">Kirazli 1998</a>; <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>; <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>; <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a>; <a href="./references#CD010362-bbs2-0007" title="YazdchiM , GhasemiZ , MoshayediH , RikhtegarR , MostafayiS , MikaileeH , et al. Comparing the efficacy of botulinum toxin with tizanidine in upper limb post stroke spasticity. Iranian Journal of Neurology2013;12(2):47‐50. ">Yazdchi 2013</a>). <a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a> measured all outcomes at an impairment level and did not attempt to assess functional change. </p> <p>Our primary objective was to determine if pharmacological interventions for spasticity are more effective than no intervention or control at improving function following stroke. Clear evidence for this was not available due to the lack of placebo‐controlled trials and the large variation in comparator trials. In the only placebo‐controlled study that employed usable outcome measures, results were inconclusive (<a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>). This trial was also the least likely to be at risk of bias. </p> <p>The results between the two placebo trials were divergent for treating spasticity, and meta‐analysis of the data produced an I<sup>2</sup> of 85%. Despite this heterogeneity in treating spasticity, there was a clear increased risk of having an adverse event associated with receiving tolperisone when compared with placebo. </p> <p>Due to the methodology employed in comparing two drugs against each other, further results were limited. Treatment in current clinical practice varies among a number of drugs, so comparative methods are not useful in this area of investigation. </p> <p>The methodology used to investigate whether the drug had indeed treated the specific impairment of spasticity varied. All of the studies used a method based on the (modified) Ashworth Scale, which has been shown to lack validity (<a href="./references#CD010362-bbs2-0048" title="FleurenJF , VoermanGE , Erren‐WoltersCV , SnoekGJ , RietmanJS , HermensHJ , et al. Stop using the Ashworth scale for the assessment of spasticity. Journal of Neurology, Neurosurgery &amp; Psychiatry2010;81(1):46‐52. ">Fleuren 2010</a>; <a href="./references#CD010362-bbs2-0066" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth scales as measures of spasticity. Clinical Rehabilitation1999;13(5):373‐83. ">Pandyan 1999</a>). Of the 79 participants who received a placebo drug, 39 (49.4%) of these improved according to the (modified) Ashworth Scale. The one study using a direct measure of one aspect of spasticity suggested that there was no difference between phenol and botulinum toxin, both of which are locally acting. This suggests a possibly large placebo effect or the effects of confounded measurement (<a href="./references#CD010362-bbs2-0048" title="FleurenJF , VoermanGE , Erren‐WoltersCV , SnoekGJ , RietmanJS , HermensHJ , et al. Stop using the Ashworth scale for the assessment of spasticity. Journal of Neurology, Neurosurgery &amp; Psychiatry2010;81(1):46‐52. ">Fleuren 2010</a>; <a href="./references#CD010362-bbs2-0066" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth scales as measures of spasticity. Clinical Rehabilitation1999;13(5):373‐83. ">Pandyan 1999</a>). </p> <p>In summary, this review has identified a lack of studies and subsequent evidence relating to the use of pharmacological interventions (with the exception of botulinum toxin) to treat spasticity. The quality of the evidence is low to very low. </p> </section> <section id="CD010362-sec-0102"> <h3 class="title" id="CD010362-sec-0102">Overall completeness and applicability of evidence</h3> <p>The completeness of evidence is limited by the methodology used in many studies. Just two out of the seven studies used a placebo control. We identified some studies using a cross‐over placebo‐controlled methodology. We contacted the authors of these cross‐over studies, but none of them responded, which meant that we could not include any of these studies in the analysis. </p> <p>The majority of outcome measures that measured function were at the activity level rather than the participation level. The measures employed differed for each study, and appropriate data were not always reported to allow analysis. </p> <p>In the two placebo‐controlled trials, there was marked heterogeneity in the results for whether the intervention had treated spasticity, which means that it is difficult to apply the evidence. The only neurophysiological measure of spasticity did not show a significant difference between phenol and botulinum toxin at 12 weeks. </p> <p>Unfortunately, despite attempts to do so, it was not possible to translate any of the full texts published in different languages into English. Until this is achieved the evidence is not fully complete. We expect to translate all of these studies into English by the time that the review is updated. </p> <p>Furthermore, due to initial editorial restrictions, we were not in a position to include botulinum toxin as a pharmacological agent. In the recent past the Cochrane Stroke Group Editorial Board has approved that this review is updated with the inclusion of botulinum neurotoxin type A. This process is ongoing, and the results will be updated once we have collated the evidence and carried out meta‐analyses. </p> </section> <section id="CD010362-sec-0103"> <h3 class="title" id="CD010362-sec-0103">Quality of the evidence</h3> <p>The quality of the evidence varied. We judged six out of seven studies to be at high risk of bias in at least one of the six methodological criteria assessed. Three of these studies had two components that we judged to be at high risk of bias. The one study we judged to have no evidence of high risk of bias did not have a judgement made in three of the six components. We judged only one study to be at low risk of bias in more than three components (<a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>). This study was one of the two placebo‐controlled studies; however, we judged the quality of the other study using this methodology to have two components at high risk of bias. </p> <p>There is a risk of reduced internal validity associated with the use of confounded measures in both the inclusion criteria for studies and outcome measures. There was also inconsistency in reporting of study results. In addition, the sample sizes in the included studies were relatively low for drug trials; three studies had 30 or fewer participants, and only two studies had a sample size of more than 100 participants. </p> </section> <section id="CD010362-sec-0104"> <h3 class="title" id="CD010362-sec-0104">Potential biases in the review process</h3> <p>Despite our extensive literature searching, selection bias is possible, and in particular publication bias. Furthermore, the inability to gain access to the secondary anonymised data from the source publications is also likely to have increased the chance of publication bias. Given the large numbers of participants in the studies awaiting classification and translation, it is possible that the current conclusions may be biased towards studies that have been published in English. We expect to translate all of these studies into English by the time that the review is updated. </p> <p>The inclusion of participants who had not had a stroke is a possible concern. However, the two studies that included participants who had survived something other than a stroke only included participants who had sustained a traumatic brain injury, and these 24 participants are unlikely to have had a major impact on any conclusions made. </p> </section> <section id="CD010362-sec-0105"> <h3 class="title" id="CD010362-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>Two previous systematic reviews have investigated this general area. A review by <a href="./references#CD010362-bbs2-0062" title="MontaneE , VallanoA , LaporteJR . Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology2004;63:1357‐63. ">Montane 2004</a> investigated oral antispastic drugs in non‐progressive neurological diseases, meaning that studies investigating traumatic brain injury, spinal cord injury, and cerebral palsy were analysed as well as stroke. This review also included the end data from cross‐over trials, which we had stated in our original protocol we would not include in our review. The authors only identified 12 studies, two of which we have included in our current review (<a href="./references#CD010362-bbs2-0001" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988;10(10):709‐18. ">Bes 1988</a>; <a href="./references#CD010362-bbs2-0004" title="MediciM , PebetM , CiblisD . A double‐blind, long‐term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Current Medical Research and Opinion1989;11(6):398‐407. ">Medici 1989</a>). They also included three studies that we excluded from our review (<a href="./references#CD010362-bbs2-0017" title="KatrakPH , ColeAM , PoulosCJ , McCauleyJC . Objective assessment of spasticity, strength, and function with early exhibition of Dantrolene sodium after cerebrovascular accident: a randomized double‐blind study. Archives of Physical Medicine and Rehabilitation1992; Vol. 73, issue 1:4‐9. ">Katrak 1992</a>; <a href="./references#CD010362-bbs2-0021" title="MedaerR , HellebuykH , Van DenBrandeE , SaxenaV , ThijsM , KovacsL , et al. Treatment of spasticity due to stroke. A double‐blind, cross‐over trial comparing baclofen with placebo. Acta Therapeutica1991;17(4):323‐31. ">Medaer 1991</a>; <a href="./references#CD010362-bbs2-0023" title="MeythalerJM , Guin‐RenfroeS , JohnsonA , BrunnerRM . Prospective assessment of tizanidine for spasticity due to acquired brain injury. Archives of Physical Medicine and Rehabilitation2001; Vol. 82, issue 9:1155‐63. ">Meythaler 2001a</a>). We excluded <a href="./references#CD010362-bbs2-0023" title="MeythalerJM , Guin‐RenfroeS , JohnsonA , BrunnerRM . Prospective assessment of tizanidine for spasticity due to acquired brain injury. Archives of Physical Medicine and Rehabilitation2001; Vol. 82, issue 9:1155‐63. ">Meythaler 2001a</a> because less than 80% of the participants had a diagnosis of stroke, and the other two studies because they were studies with a cross‐over design. Despite the methodological differences between the <a href="./references#CD010362-bbs2-0062" title="MontaneE , VallanoA , LaporteJR . Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology2004;63:1357‐63. ">Montane 2004</a> review and our review, the conclusions were similar. </p> <p>A more recent review by <a href="./references#CD010362-bbs2-0064" title="OlveyEL , ArmstrongEP , GrizzleAJ . Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clinical Therapeutics2010;32(14):2282‐303. ">Olvey 2010</a> investigated only people with a history of stroke but also specifically arm spasticity. This review used just nine search terms and included only drugs available commercially in the United States. The methodology also included studies that were not randomised. Importantly, this review included studies which investigated botulinum toxin. Of the 54 studies that met the inclusion criteria, 51 of them involved botulinum toxin. The other three studies were uncontrolled trials of tizanidine and intrathecal baclofen, and one cross‐over trial investigating intrathecal baclofen that we excluded from our review (<a href="./references#CD010362-bbs2-0022" title="MeythalerJM , Guin‐RenfroeS , BrunnerRC , HadleyMN . Intrathecal baclofen for spastic hypertonia from stroke. Stroke. Department of Physical Medicine and Rehabilitation, Division of Neurological Surgery, University of Alabama at Birmingham School of Medicine, Birmingham, USA. JMeythal@uab.edu, 2001; Vol. 32, issue 9:2099‐109. ">Meythaler 2001</a>). The one trial that was included in both the review by <a href="./references#CD010362-bbs2-0064" title="OlveyEL , ArmstrongEP , GrizzleAJ . Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clinical Therapeutics2010;32(14):2282‐303. ">Olvey 2010</a> and our review was <a href="./references#CD010362-bbs2-0005" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , Team TBS. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(4):380‐5. ">Simpson 2009</a>. Due to methodological differences, it is not appropriate to compare our review with <a href="./references#CD010362-bbs2-0064" title="OlveyEL , ArmstrongEP , GrizzleAJ . Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clinical Therapeutics2010;32(14):2282‐303. ">Olvey 2010</a>. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010362-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010362-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010362-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010362-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Systemic drug versus placebo, Outcome 1 Function." data-id="CD010362-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Systemic drug versus placebo, Outcome 1 Function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Systemic drug versus placebo, Outcome 2 Spasticity ‐ indirect measure." data-id="CD010362-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Systemic drug versus placebo, Outcome 2 Spasticity ‐ indirect measure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Systemic drug versus placebo, Outcome 3 Adverse events." data-id="CD010362-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Systemic drug versus placebo, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic drug versus another systemic drug, Outcome 1 Function." data-id="CD010362-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Systemic drug versus another systemic drug, Outcome 1 Function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic drug versus another systemic drug, Outcome 2 Function dichotomous." data-id="CD010362-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Systemic drug versus another systemic drug, Outcome 2 Function dichotomous.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic drug versus another systemic drug, Outcome 3 Spasticity ‐ indirect measure." data-id="CD010362-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Systemic drug versus another systemic drug, Outcome 3 Spasticity ‐ indirect measure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic drug versus another systemic drug, Outcome 4 Clonus." data-id="CD010362-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Systemic drug versus another systemic drug, Outcome 4 Clonus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic drug versus another systemic drug, Outcome 5 Muscle spasms." data-id="CD010362-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Systemic drug versus another systemic drug, Outcome 5 Muscle spasms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Systemic drug versus another systemic drug, Outcome 6 Adverse events." data-id="CD010362-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Systemic drug versus another systemic drug, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemically acting drug versus a locally acting drug, Outcome 1 Function." data-id="CD010362-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Systemically acting drug versus a locally acting drug, Outcome 1 Function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Systemically acting drug versus a locally acting drug, Outcome 2 Adverse events." data-id="CD010362-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Systemically acting drug versus a locally acting drug, Outcome 2 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Locally acting drug versus another locally acting drug, Outcome 1 Function." data-id="CD010362-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Locally acting drug versus another locally acting drug, Outcome 1 Function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Locally acting drug versus another locally acting drug, Outcome 2 Passive range of movement." data-id="CD010362-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Locally acting drug versus another locally acting drug, Outcome 2 Passive range of movement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Locally acting drug versus another locally acting drug, Outcome 3 Spasticity ‐ neurophysiological." data-id="CD010362-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Locally acting drug versus another locally acting drug, Outcome 3 Spasticity ‐ neurophysiological. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Locally acting drug versus another locally acting drug, Outcome 4 Spasticity ‐ indirect measure." data-id="CD010362-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Locally acting drug versus another locally acting drug, Outcome 4 Spasticity ‐ indirect measure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Locally acting drug versus another locally acting drug, Outcome 5 Clonus." data-id="CD010362-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Locally acting drug versus another locally acting drug, Outcome 5 Clonus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010362-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/urn:x-wiley:14651858:media:CD010362:CD010362-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_t/tCD010362-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Locally acting drug versus another locally acting drug, Outcome 6 Adverse events." data-id="CD010362-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Locally acting drug versus another locally acting drug, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/media/CDSR/CD010362/image_n/nCD010362-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010362-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Systemic antispasticity drugs compared with placebo for spasticity after stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Systemic antispasticity drugs compared with placebo for spasticity after stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with spasticity following stroke<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> systemic antispasticity drugs<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Systemic antispasticity drugs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Indirect measure of spasticity</b> <br/> Modified Ashworth Scale<br/> Follow‐up: 4 or 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 1.66</b> <br/> (0.12 to 15.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>160<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 100</b> <br/> (10 to 94) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events</b> <br/> Adverse events per participant<br/> Follow‐up: 4 or 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.65</b> <br/> (1.12 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>160<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 100</b> <br/> (44 to 96) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Unclear how random sequence generation was carried out in either study.<br/> <sup>2</sup>Results very heterogenous (I<sup>2</sup> = 90%).<br/> <sup>3</sup>The studies did not investigate the same drug against a placebo.<br/> <sup>4</sup>Both studies appeared to selectively report results. The corresponding author of the <a href="./references#CD010362-bbs2-0006" title="StamenovaP , KoytchevR , KuhnK , HansenC , HorvathF , RammS , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. European Journal of Neurology2005;12(6):453‐61. ">Stamenova 2005</a> study was an employee of the company that manufactured the drug. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Systemic antispasticity drugs compared with placebo for spasticity after stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010362-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pharmacological agents for treating spasticity after stroke</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Generic name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Method of administration</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Method of action</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baclofen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral, intrathecal pump</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baclofen is a centrally acting gamma‐aminobutyric acid (GABA) analogue that limits the release of excitatory neurotransmitters in the spinal cord (<a href="./references#CD010362-bbs2-0063" title="MukherjeeA , ChakravartyA . Spasticity mechanisms ‐ for the clinician. Frontiers in Neurology2010;1:149. ">Mukherjee 2010</a>). It binds to GABA receptors at the presynaptic terminal and inhibits the influx of calcium into the presynaptic terminal, decreasing both mono‐ and polysynaptic reflexes (<a href="./references#CD010362-bbs2-0045" title="DavidoffRA . Antispasticity drugs: mechanisms of action. Annals of Neurology1985;17(2):107‐16. ">Davidoff 1985</a>; <a href="./references#CD010362-bbs2-0055" title="KrachLE . Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. Journal of Child Neurology2001;16(1):31‐6. ">Krach 2001</a>). It also binds on the postsynaptic terminal of the 1a sensory afferent (<a href="./references#CD010362-bbs2-0054" title="HoweJR , SutorB , ZieglgänsbergerW . Baclofen reduces post‐synaptic potentials of rat cortical neurones by an action other than its hyperpolarizing action. Journal of Physiology1987;384:539‐69. ">Howe 1987</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An imidazole derivative with agonist action on alpha‐2‐adrenergic receptors in the central nervous system (<a href="./references#CD010362-bbs2-0063" title="MukherjeeA , ChakravartyA . Spasticity mechanisms ‐ for the clinician. Frontiers in Neurology2010;1:149. ">Mukherjee 2010</a>). It has an effect both pre‐ and postsynaptically and decreases the level of excitatory neurotransmitter between the spinal interneurons to the alpha motor neurons through presynaptic inhibition (<a href="./references#CD010362-bbs2-0049" title="GallichioJE . Pharmacologic management of spasticity following stroke. Physical Therapy2004;84(10):973‐81. ">Gallichio 2004</a>). It may also inhibit abnormal activity by acting on locus coeruleus and inhibiting activity in the coerulospinal pathway (<a href="./references#CD010362-bbs2-0065" title="PalmeriA , WiesendangerM . Concomitant depression of locus coeruleus neurons and of flexor reflexes by an alpha 2‐adrenergic agonist in rats: a possible mechanism for an alpha 2‐mediated muscle relaxation. Neuroscience1990;34(1):177‐87. ">Palmeri 1990</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dantrolene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This drug acts at the muscle level rather than the neural level and affects both intra‐ and extrafusal muscles (<a href="./references#CD010362-bbs2-0049" title="GallichioJE . Pharmacologic management of spasticity following stroke. Physical Therapy2004;84(10):973‐81. ">Gallichio 2004</a>). It interferes with the release of calcium from the sarcoplasmic reticulum of the muscle (<a href="./references#CD010362-bbs2-0063" title="MukherjeeA , ChakravartyA . Spasticity mechanisms ‐ for the clinician. Frontiers in Neurology2010;1:149. ">Mukherjee 2010</a>). This decrease in available calcium reduces the force produced during a contraction (<a href="./references#CD010362-bbs2-0049" title="GallichioJE . Pharmacologic management of spasticity following stroke. Physical Therapy2004;84(10):973‐81. ">Gallichio 2004</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolperisone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Centrally acting muscle relaxant that acts at the spinal cord level. Primarily acts presynaptically to inhibit both calcium and sodium channels. Decreases reflex activity by inhibiting release from the primary afferent (<a href="./references#CD010362-bbs2-0077" title="VoraA . Tolperisone. Journal of the Association of Physicians of India2010;58:127‐8. ">Vora 2010</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alcohol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of alcohol varies depending on the concentration. At concentrations below 35%, it acts as a local anaesthetic. In concentrations between 35% to 50% small‐fibre demyelination was observed, but in concentrations above this level, Wallerian degeneration and fibrosis are observed (<a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injection, intrathecal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of phenol also varies depending on concentrations used. It can be injected either into the muscle or directly into the nerve. At concentrations greater than 3%, protein denaturation and axonal degeneration destroy the neurons. 5% phenol injection to the motor points of the muscle lead to demyelination of the neuron (<a href="./references#CD010362-bbs2-0003" title="KocabasH , SalliA , DemirAH , OzerbilOM . Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical &amp; Rehabilitation Medicine2010;46(1):5‐10. ">Kocabas 2010</a>). </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pharmacological agents for treating spasticity after stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010362-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Factors that may decrease the quality of the evidence</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Limitations in the design and implementation of available studies suggesting high likelihood of bias </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Indirectness of evidence (indirect population, intervention, control, outcomes)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Imprecision of results (wide confidence intervals)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. High probability of publication bias</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Factors that may decrease the quality of the evidence</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/full#CD010362-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010362-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic drug versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.90, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Disability Assessment Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.90, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Spasticity ‐ indirect measure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.21, 13.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adverse events per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.12, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants withdrawn due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.04, 34.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic drug versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010362-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Systemic drug versus another systemic drug</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Gait</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐183.3 [‐330.40, ‐36.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Pedersen Scale ‐ upper limb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.23, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pedersen Scale ‐ lower limb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.17, 5.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Spasticity ‐ indirect measure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tizanidine versus baclofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.36, 15.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tizanidine versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.37, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clonus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tizanidine versus baclofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.04, 9.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tizanidine versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.4 [0.44, 4.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Muscle spasms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Tizanidine versus baclofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 4.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Per participant ‐ tizanidine versus baclofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.1 [0.83, 5.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Total‐ tizanidine versus baclofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.94, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Total ‐ tizanidine versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.01, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Withdrew ‐ tizanidine versus baclofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Withdrew ‐ tizanidine versus diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.18, 1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Systemic drug versus another systemic drug</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010362-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Systemically acting drug versus a locally acting drug</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Action Research Arm Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.79 [‐6.93, ‐0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>41.00 [2.58, 651.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Systemically acting drug versus a locally acting drug</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010362-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Locally acting drug versus another locally acting drug</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Gait (25 feet timed walk)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐2.83, 8.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Passive range of movement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Phenol versus alcohol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐7.00, 11.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Spasticity ‐ neurophysiological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 H:M Ratio</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.48, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 H‐reflex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [‐1.44, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Spasticity ‐ indirect measure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Phenol versus alcohol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.02, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clonus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Phenol versus alcohol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.56 [0.34, 212.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Total ‐ phenol versus alcohol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.41, 120.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Total ‐ phenol versus botulinum toxin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.41, 120.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Locally acting drug versus another locally acting drug</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010362.pub2/references#CD010362-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010362.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010362-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010362-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010362-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010362-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010362-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010362-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010362\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010362\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010362\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010362\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010362\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010362.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010362.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010362.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010362.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010362.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717272056"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010362.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717272060"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010362.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db3e06a639365',t:'MTc0MDcxNzI3Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 